US 9,809,654 B2
Targeted CD1d molecules
Bruno Robert, Saint Hippolyte du Four (FR); Alena Donda, Les Cullayes (CH); Valerie Cesson, Saint Gingolph (FR); Jean-Pierre Mach, Bellevue (CH); and Maurice Zauderer, Pittsford, NY (US)
Assigned to Vaccinex, Inc., Rochester, NY (US)
Appl. No. 10/529,221
Filed by Bruno Robert, Saint Hippolyte du Four (FR); Alena Donda, Les Cullayes (CH); Valerie Cesson, Saint Gingolph (FR); Jean-Pierre Mach, Bellevue (CH); and Maurice Zauderer, Pittsford, NY (US)
PCT Filed Sep. 26, 2003, PCT No. PCT/US03/30238
§ 371(c)(1), (2), (4) Date Jun. 30, 2006,
PCT Pub. No. WO2004/029206, PCT Pub. Date Apr. 8, 2004.
Claims priority of application No. 02405838 (EP), filed on Sep. 27, 2002.
Prior Publication US 2006/0269540 A1, Nov. 30, 2006
Int. Cl. C07K 19/00 (2006.01); C07K 16/30 (2006.01); C07K 14/74 (2006.01); A61K 35/17 (2015.01)
CPC C07K 16/30 (2013.01) [C07K 14/70539 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2319/00 (2013.01)] 29 Claims
 
1. A compound comprising:
(a) a soluble CD1d complex comprising:
i) a CD1d molecule or antigen-binding fragment thereof;
ii) a β2-microglobulin molecule or fragment thereof; and
iii) a stimulatory glycolipid antigen bound in the antigen binding groove of the CD1d molecule or antigen-binding fragment thereof; and
(b) an antibody or an antigen-binding fragment thereof specific for a cell surface marker of a tumor cell;
wherein said CD1d complex is linked to said antibody or fragment thereof; and wherein said compound stimulates the activation of the cytolytic activity of NKT cells.